MIST vs. ORGO, KMDA, KALV, ABVX, AURA, RVNC, ALLO, PRME, KOD, and TERN
Should you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Organogenesis (ORGO), Kamada (KMDA), KalVista Pharmaceuticals (KALV), ABIVAX Société Anonyme (ABVX), Aura Biosciences (AURA), Revance Therapeutics (RVNC), Allogene Therapeutics (ALLO), Prime Medicine (PRME), Kodiak Sciences (KOD), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry.
Milestone Pharmaceuticals vs.
Organogenesis (NASDAQ:ORGO) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.
Organogenesis has higher revenue and earnings than Milestone Pharmaceuticals. Organogenesis is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Organogenesis had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 8 mentions for Organogenesis and 7 mentions for Milestone Pharmaceuticals. Organogenesis' average media sentiment score of 1.20 beat Milestone Pharmaceuticals' score of 0.62 indicating that Organogenesis is being referred to more favorably in the media.
Milestone Pharmaceuticals has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Organogenesis' return on equity of -2.69% beat Milestone Pharmaceuticals' return on equity.
Organogenesis presently has a consensus price target of $5.00, suggesting a potential upside of 30.89%. Milestone Pharmaceuticals has a consensus price target of $13.00, suggesting a potential upside of 541.98%. Given Milestone Pharmaceuticals' higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Organogenesis.
Organogenesis received 15 more outperform votes than Milestone Pharmaceuticals when rated by MarketBeat users. However, 69.49% of users gave Milestone Pharmaceuticals an outperform vote while only 66.44% of users gave Organogenesis an outperform vote.
49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 36.9% of Organogenesis shares are owned by insiders. Comparatively, 9.9% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Organogenesis has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.
Summary
Organogenesis beats Milestone Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Milestone Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Milestone Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:MIST) was last updated on 1/28/2025 by MarketBeat.com Staff
